EOLS

6.6604.86%
RA

Rui Avelar

Chief Medical Officer and Head of Research & Development

Dr. Rui Avelar, M.D., CCFP, DIP SPORT MED, serves as Chief Medical Officer at Evolus, Inc. since January 2014 and Head of Research & Development since August 15, 2018. Dr. Avelar served as the Chief Medical Officer at ALPHAEON Corporation until January 2018. Dr. Avelar served as Chief Medical Officer of Angiotech Pharmaceuticals Inc. since December 19, 2005. He served as Senior Vice President of Medical Affairs and Communications of Angiotech Pharmaceuticals Inc. from January 2004 to December 2005. He served as Vice President of Medical Affairs and Communications of Angiotech Pharmaceuticals Inc. from January 2003 to January 2004 and Vice President of Investor Relations from December 2001 to January 2003. He joined Angiotech in December 2001. From March 2011 to December 2013, he served as Chief Medical Officer of Allergan Medical. He was responsible for representing Angiotech to the investment community and overseeing medical, public and media relations strategies. He was increasingly involved in medical market analysis, product development and clinical trial design. He served as Securities Analyst of Haywood Securities Inc. The 10 years prior, he had an established medical practice, specializing in sports medicine. He serves as a Lecturer of Continuing Medical Education as well as the Team Physician of the Vancouver Canucks hockey organization. He is a Member of the College of Physicians and Surgeons of British Columbia and the Academy of Sports Medicine. Dr. Avelar received his Medical Degree from the University of Toronto in 1989 and then went on to complete a residency. He proceeded to receive additional training and his Sports Medicine Certification from the Canadian Academy of Sports Medicine in Ottawa in 1994. His Undergraduate Studies included Microbiology, Biochemistry, Physics and Organic Chemistry.

Positions